BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Beruzatatug pelitecan readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Beruzatatug pelitecan\, from ClinicalTria
 ls.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06107686-1982@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Beruzatatug pelitecan: Phase 2 readout est. (NCT06107686)
DESCRIPTION:Beruzatatug pelitecan\, phase 2\, Non-Small Cell Lung Cancer.\n
 Study: A Study of YL202 in Selected Patients With Advanced Solid Tumors\nE
 stimated primary completion: November 2026. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/beruzatatug-pelitecan#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT06107686
URL:https://assetmemo.bio/drug/beruzatatug-pelitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05653752-1982@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Beruzatatug pelitecan: Phase 1 readout est. (NCT05653752)
DESCRIPTION:Beruzatatug pelitecan\, phase 1\, Non-Small Cell Lung Cancer.\n
 Study: A Study of YL202 in Patients With Locally Advanced or Metastatic No
 n-small Cell Lung Cancer and Breast Cancer\nEstimated primary completion: 
 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/beruza
 tatug-pelitecan#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT05653752
URL:https://assetmemo.bio/drug/beruzatatug-pelitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07202364-1982@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Beruzatatug pelitecan: Phase 2 readout est. (NCT07202364)
DESCRIPTION:Beruzatatug pelitecan\, phase 2\, Non-Small Cell Lung Cancer.\n
 Study: A Study of YL202 in Patients With Advanced Solid Tumors\nEstimated 
 primary completion: 31 January 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/beruzatatug-pelitecan#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07202364
URL:https://assetmemo.bio/drug/beruzatatug-pelitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06439771-1982@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:Beruzatatug pelitecan: Phase 2 readout est. (NCT06439771)
DESCRIPTION:Beruzatatug pelitecan\, phase 2\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: A Phase 2 Study to Evaluate the Efficacy\, Safety and Pharm
 acokinetics of YL202 in Patients With BC\nEstimated primary completion: 30
  July 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/beruzatat
 ug-pelitecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT06439771
URL:https://assetmemo.bio/drug/beruzatatug-pelitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07461454-1982@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Beruzatatug pelitecan: Phase 3 readout est. (NCT07461454)
DESCRIPTION:Beruzatatug pelitecan\, phase 3\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: YL202 Versus Treatment of Physician's Choice in Patients Wi
 th HR+/HER2- Breast Cancer\nEstimated primary completion: 31 December 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/beruzatatug-pelitec
 an#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7461454
URL:https://assetmemo.bio/drug/beruzatatug-pelitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07070232-1982@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Beruzatatug pelitecan: Phase 1/2 readout est. (NCT07070232)
DESCRIPTION:Beruzatatug pelitecan\, phase 1/2.\nStudy: A Clinical Study to 
 Test if an Investigational Treatment Called BNT326 is Safe and Potentially
  Beneficial When Used Alone or in Combination With Other Investigational T
 reatments Such as BNT327\, for People With Advanced Malignant Tumors\nEsti
 mated primary completion: March 2028. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/beruzatatug-pelitecan#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07070232
URL:https://assetmemo.bio/drug/beruzatatug-pelitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07416994-1982@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Beruzatatug pelitecan: Phase 3 readout est. (NCT07416994)
DESCRIPTION:Beruzatatug pelitecan\, phase 3\, Non-Small Cell Lung Cancer.\n
 Study: Pivotal Study to Evaluate YL202 Versus Docetaxel in Patients With L
 ocally Advanced or Metastatic EGFR Sensitive Mutation Non-Squamous Non-Sma
 ll Cell Lung Cancer\nEstimated primary completion: 31 August 2028. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/beruzatatug-pelitecan#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07416994
URL:https://assetmemo.bio/drug/beruzatatug-pelitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07111520-1982@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Beruzatatug pelitecan: Phase 1/2 readout est. (NCT07111520)
DESCRIPTION:Beruzatatug pelitecan\, phase 1/2\, Non-Small Cell Lung Cancer.
 \nStudy: A Clinical Trial to Test if an Investigational Combination Therap
 y With BNT326 and BNT327 is Safe and Potentially Beneficial for People Wit
 h Advanced Non-small Cell Lung Cancer (NSCLC)\nEstimated primary completio
 n: November 2028. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ber
 uzatatug-pelitecan#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07111520
URL:https://assetmemo.bio/drug/beruzatatug-pelitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
